Patents by Inventor Yuri D. Ivashchenko

Yuri D. Ivashchenko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Akt Nucleic Acids, Polypeptides, and Uses Thereof
    Publication number: 20120034188
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Application
    Filed: August 1, 2011
    Publication date: February 9, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Kun Guo, Marco F. Pagnoni, Kenneth L. Clark, Yuri D. Ivashchenko
  • AKT nucleic acids, polypeptides, and uses thereof
    Patent number: 7989584
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: August 2, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Kun Guo, Kenneth L. Clark, Yuri D. Ivashchenko, Marco Pagnoni
  • AKT NUCLEIC ACIDS, POLYPEPTIDES, AND USES THEREOF
    Publication number: 20100143308
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Application
    Filed: December 9, 2009
    Publication date: June 10, 2010
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Kun GUO, Marco F. PAGNONI, Kenneth L. CLARK, Yuri D. IVASHCHENKO
  • Human Akt3 nucleic acid and uses thereof
    Patent number: 7662628
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: February 16, 2010
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Kun Guo, Kenneth L. Clark, Yuri D. Ivashchenko, Marco Pagnoni
  • Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNF?) signaling pathway
    Patent number: 7332593
    Abstract: The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF ? signaling pathway. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as “TRAF2 truncated-deleted” or “TRAF2TD”. Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF ? signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF ? binding.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: February 19, 2008
    Assignee: sanofi-aventis U.S. LLC
    Inventors: George H. Searfoss, III, Marco F. Pagnoni, Yuri D. Ivashchenko, Kun Guo, Kenneth L. Clark
  • Variants of traf2 which act as an inhibitor of tnf-alpha (tnf?) signaling pathway
    Patent number: 6998475
    Abstract: The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF ? signaling path-way. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as “TRAF2 truncated-deleted” or “TRAF2TD”. Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF ? signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF ? binding.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: February 14, 2006
    Assignee: Centelion SAS
    Inventors: George H. Searfoss, III, Marco F. Pagnoni, Yuri D. Ivashchenko, Kun Guo, Kenneth L. Clark
  • AKT nucleic acids, polypeptides, and uses thereof
    Patent number: 6881555
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: April 19, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Kun Guo, Marco F. Pagnoni, Kenneth L. Clark, Yuri D. Ivashchenko
  • AKT nucleic acids, polypeptides, and uses thereof
    Publication number: 20030100049
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Application
    Filed: March 14, 2000
    Publication date: May 29, 2003
    Inventors: Kun Guo, Marco F. Pagnoni, Kenneth L. Clark, Yuri D. Ivashchenko
  • Expression cloning of c-src SH3-domain binding proteins
    Patent number: 5541109
    Abstract: This invention provides a unique SH3 binding domain core motif of the sequence RPLPXXP and cDNA clones encoding proteins which interact with the SH3 domain of c-src, as well as the amino acid sequences which mediate this binding.Another embodiment of this invention is a method of identifying SH3-binding proteins and elucidating the sequences which mediate binding. This method may be used as an assay to select compounds which bind to this site and which inhibit or enhance the binding of the SH3 domain.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: July 30, 1996
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: George H. Searfoss, III, Yuri D. Ivashchenko, Michael C. Jaye, Victoria J. South, Stephen M. French, Christopher Cheadle, George A. Ricca